Q2 Recovery Expected
Management expects Q2 revenues to improve from Q1 levels based on ARV formulation order book visibility and sequential volume improvement in APIs and formulations.
LAURUSLABS / guidance tracker
Keep management guidance in view.
Laurus Labs · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
FY2024 Consolidation Year
FY2024 remains a consolidation year with no change to prior guidance; management indicates they are on par with or better than internal targets.
FDF Capacity Ramp
FDF capacity utilization expected to increase from 5 billion to 7 billion units by FY24 year-end as brownfield expansions come online.
Animal Health Commercial Supply H2 FY25
Animal health site commercial validations begin October 2023; meaningful revenue contribution expected from H2 FY25 with full-year impact in FY25.
FY25 EBITDA Margin Target of ~20%
Management maintained confidence in achieving ~20% EBITDA margin target for FY25, expecting H2 performance improvement as CDMO project deliveries and new initiatives ramp up.
ARV Franchise Revenue Guidance of INR 2,400-2,500 crore
ARV APIs and formulations expected to remain around INR 2,400-2,500 crore despite investment reallocation, with quantum remaining stable as percentage contribution declines from other businesses.
Net Debt/EBITDA Target Below 2.5x by March 2025
Company targeting leverage ratio improvement to less than 2.5x by end of FY25, down from current ~3.3x, as EBITDA recovers with higher capacity utilization.
Vizag Fermentation Facility by June 2026
INR 200 crore investment for larger fermentation capacity at Vizag, breaking ground now, expected to be commissioned by mid-2026 for GMP pharmaceutical manufacturing.
55-60% Gross Margin Range
Management expects gross margins to sustain in the 55-60% range going forward as CDMO contribution increases, up from the previous ~55% guidance.
Non-ARV Formulation Growth from Q4
Capacity expansion for non-ARV formulations is underway with qualification expected by end of FY26, enabling growth acceleration from Q4 onwards.
FY26 Revenue Guidance: INR 2,500Cr+ for CDMO
CDMO segment expected to achieve INR 2,500 crore plus range for FY26, with good visibility on molecules, volumes, customers and pricing.
INR 5,000Cr CapEx Over 4-5 Years
Company announced INR 5,000 crore cumulative CapEx investment over 4-5 years, funded primarily through internal accruals, maintaining net debt below 50% of revenue.
H2 FY2024 EBITDA margin improvement over H1
Management expects margins will be better than the first half based on current growth trends across all segments and healthy order book.
FY2024 full-year R&D spend at 4.5% of sales
R&D expenditure guidance maintained at 4.5% of sales for the full year, with higher spend in Q2 due to acquisition of gene therapy IP from IIT Kanpur.
Target ~30% EBITDA margin when facilities fully utilized
CEO committed the company will return to approximately 30% EBITDA levels as new CDMO, animal health, and synthesis facilities achieve commercial scale, expected from mid-FY2025 onwards.
CDMO revenues to normalize in FY2025
No new commercial CDMO sales expected in next 12-18 months; human health projects moving from phase II to phase III will drive recovery next financial year.
FY25 EBITDA margin ~20%
Management expects H2 improvement as CDMO project deliveries ramp and operational deleverage cycle concludes. Currently at end of deleverage period.
CDMO FY25 growth driven by H2 deliveries
FY24 CDMO revenue was INR 922 crore; H1 FY25 achieved INR 553 crore. High-value late-phase clinical projects scheduled for Q4 recognition.
Net debt to remain below INR 3,000 crore
Current net debt at INR 2,679 crore; management expects improvement based on H2 performance. QIP not being considered at this juncture.
Effective tax rate ~28%
Historical effective tax rate of approximately 28% applicable for H2 FY25, after lower rate in H1.
FY26 CapEx of INR 1,000 crore
Company invested INR 489 crore in H1 and expects to invest similar amount in H2, maintaining aggressive capital deployment for capacity expansion.
Asset Turnover Target: 1.1x
Progressing from current 0.9x to historical average of 1.1x; management expects improvement over coming years as capacities reach full utilization.
EBITDA Margin Improvement
Operating leverage expected to continue improving margins as CDMO commercial molecule mix grows and asset utilization increases.
ARV FY26 Outlook: INR 2,500 crore ± INR 200 crore
Full-year antiretroviral sales guidance maintained despite H1 achieving INR 1,380 crore; management expects H2 to be relatively softer.
H2 FY24 better than H1 FY24
Management reiterated commitment to H2 FY24 being better than H1 FY24, citing healthy order book and strong commercial execution expected from Q4 onwards.
EBITDA margin to improve significantly towards >20%
Management expects EBITDA margins to move from current ~15% to "definitely beyond 20%" as sales volumes increase, with most incremental gross margin flowing through to EBITDA.
Asset turn to improve from 0.9x to 1.1x
Current asset turn at 0.9x with 5-year average of 1.1x and peak of 1.4x. Revenue should scale with capacity utilisation improvement across CDMO, Bio, and FDF businesses.
FY24 R&D spend at 4.5% of revenue
Full year R&D spend expected at 4.5% of sales, focused on pipeline enhancement including gene therapy initiatives. 61 products in R&D pipeline across various markets.
FY2025 EBITDA margin ~20%
Management reiterated full-year EBITDA margin guidance of ~20%, implying H2 margin improvement driven by CDMO ramp-up and operating leverage.
FY2026: Better year for CDMO
CEO explicitly stated FY2026 will be a 'better year for CDMO' than FY2025, citing robust pipeline, multiple commercial programs, and animal health growth.
Vizag fermentation facility operational by end-2026
Laurus Bio's large-scale 2-million-liter fermentation capacity at Vizag expected to be operational by end-CY2026, more than doubling current capacity with Eight Roads as strategic partner.
GMP viral vector facility in FY2026
Investment of INR 120-130 crore into GMP-scale facility for viral vectors and plasmids CMO, expected operational in FY2026.
FY2026 CapEx of INR 1,000 crore
Annual capital expenditure expected at INR 1,000 crore for FY2026, with similar levels anticipated for FY2027 as well, supporting capacity expansions across peptides, KRKA, and ADC facilities.
Gross margin sustainability at 60%
Management expects to maintain gross margins of approximately 60% in the coming quarters and through the next financial year, supported by favorable product mix and process improvements.
ARV revenue guidance of INR 2,600 ± 200 crore
Revised ARV annual revenue guidance to INR 2,600 ± 200 crore, up from prior INR 2,500 ± 200 crore, driven by expanded API capacities meeting customer demand.
Target asset turnover of 1.1x
Management targets improving asset turnover from current 0.91x toward 1.1x (five-year average) over time, with peak historical performance at 1.4x.
CDMO contribution target of one-third of revenue
Management expects CDMO (including synthesis and bio) to grow from ~20% to approximately one-third of total revenue in the next couple of years, driven by Animal Health commercialization and new client additions.
Animal Health commercial supplies to begin FY2025, peak FY2027
Animal Health facility (fully contracted with big pharma partner) will start commercial supplies in FY2025, with peak revenues expected in FY2027. Commercial validation for ~4 products will be completed this financial year.
CGT (Gene Therapy) GLP/GMP plant operational by end Q3 FY2025
GLP/GMP plant construction for viral vectors and gene therapy products at IIT Kanpur is underway, targeting Phase 1 operations by end of Q3 FY2025. CapEx and OpEx could be ~INR 300 crore over next 2-3 years, contingent on clinical trial progress.
Bio unit peak revenues expected in FY2025
Biologics division is expected to achieve peak revenues during FY2025, with downstream R2 capacity increased by 20% and enzyme engineering expanding for small molecule, clinical and commercial API projects.
FY2026 Revenue and Profitability Growth
Management expects significant growth in both revenues and profits for FY2026 compared to FY2025, driven by CDMO expansion and better asset utilization.
EBITDA Margin Improvement
Operating margins expected to improve from better asset utilization and favorable product mix as CDMO contribution increases.
FY2026 CapEx of INR 1,000 crore
CapEx guidance of ~INR 1,000 crore for FY26, primarily for formulation CMO expansion, fermentation facility (INR 250 crore in Visakhapatnam), and API/CDMO production blocks.
Non-ARV Formulation Revenue Growth from Q3
Non-ARV formulation revenue will increase from Q3 onwards due to new US/Canada approvals and CMO partner expansion commissioning in Q4 CY25.
Capex of ₹3,000 crore over next two years
Increased from earlier ₹1,000 crore annually; 90% towards mid/large-scale manufacturing.
CDMO to reach 50% of total sales by 2030
Management reiterated target; ARV sales to remain constant in absolute terms.
EBITDA margin to sustain or improve in FY27
Confident in maintaining stable margins despite solvent price pressures.
Unit 7 first production block ready by March 2027
Greenfield project; additional blocks in FY28 with combined 2,000 m³ reactor volume.